Immunocytochemical and lectin histochemical studies of plaques and tangles in Down's syndrome patients at different ages
- PMID: 2532371
Immunocytochemical and lectin histochemical studies of plaques and tangles in Down's syndrome patients at different ages
Abstract
The presence of numerous senile plaques (SP) and neurofibrillary tangles (NFT) within association areas of the neocortex and within the hippocampus and amygdala, is generally regarded as providing the histopathological hallmarks of Alzheimer's disease (AD) (Mann, 1985). Similar pathological changes, to those of AD, are seen in the brains of nearly all persons with Down's syndrome (DS) who live beyond 40 years of age, though such features are only rarely seen before 20 years of age (Mann, 1988). Because of this similarity between AD and DS at middle age, DS has been considered (Mann, 1988) to provide a useful model for the pathological process of AD. Hence a study of DS patients at different ages (and in all of whom the pathological changes typical of AD would have been expected had they lived long enough) can provide important data concerning the time course of the acquisition and the morphological and biochemical genesis of SP and NFT in DS, with obvious implications as to the changes of AD itself. In this study, the brains of 24 patients dying, between the ages of 13 and 65 years, with DS have been examined for the presence and the morphological appearance of SP and NFT using various markers for structural or biochemical components known, from previous work on AD (Ihara, 1988; Ihara et al., 1986; Davies et al., 1988; Mann et al., 1988) to be associated with SP and NFT.
Similar articles
-
Histopathological studies on senile plaques in brains of patients with Down's syndrome.Kobe J Med Sci. 1990 Dec;36(5-6):153-71. Kobe J Med Sci. 1990. PMID: 1708000
-
Gender differences in the phenotypic expression of Alzheimer's disease in Down's syndrome (trisomy 21).Neuroreport. 1994 Jun 27;5(11):1393-6. Neuroreport. 1994. PMID: 7919207
-
Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.Neurobiol Dis. 1996 Feb;3(1):16-32. doi: 10.1006/nbdi.1996.0003. Neurobiol Dis. 1996. PMID: 9173910
-
Alteration of neuritic cytoarchitecture in Alzheimer disease.Prog Clin Biol Res. 1989;317:781-9. Prog Clin Biol Res. 1989. PMID: 2690122 Review.
-
Neuropathology of Down syndrome and Alzheimer disease.Am J Med Genet Suppl. 1990;7:282-6. doi: 10.1002/ajmg.1320370756. Am J Med Genet Suppl. 1990. PMID: 2149963 Review.
Cited by
-
Amyloid beta: structure, biology and structure-based therapeutic development.Acta Pharmacol Sin. 2017 Sep;38(9):1205-1235. doi: 10.1038/aps.2017.28. Epub 2017 Jul 17. Acta Pharmacol Sin. 2017. PMID: 28713158 Free PMC article. Review.
-
Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain.Biochem J. 2014 Oct 15;463(2):177-89. doi: 10.1042/BJ20140772. Biochem J. 2014. PMID: 25242166 Free PMC article. Review.
-
Combination therapy prevents amyloid-dependent and -independent structural changes.Neurobiol Aging. 2012 Jul;33(7):1273-83. doi: 10.1016/j.neurobiolaging.2010.12.007. Epub 2011 Jan 22. Neurobiol Aging. 2012. PMID: 21257234 Free PMC article.
-
Olfaction in People with Down Syndrome: A Comprehensive Assessment across Four Decades of Age.PLoS One. 2016 Jan 5;11(1):e0146486. doi: 10.1371/journal.pone.0146486. eCollection 2016. PLoS One. 2016. PMID: 26730728 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical